Successful treatment of widespread eczema and sleep disruption in a 7-month-old infant with methylprednisolone aceponate 0.1%.
A 7-month-old infant, with no known food allergy or intolerance, presenting with eczema lesions affecting many parts of his body, was diagnosed with infantile eczema. A skin barrier defect, due to filaggrin deficiency, was suspected. Prior treatment with emollients was not effective and produced discomfort. After twice-daily application of methylprednisolone aceponate (MPA) 0.1% (Advantan(®)), in addition to temporary withdrawal of emollients, for 10 days. At the follow-up examination, improvements in all eczema lesions, scratching behavior and sleep quality were observed, and eczema was considered almost clear and under control. Advantan was prescribed to control new flares of eczema, and heavy emollients were recommended to treat residual dryness and damage from original lesions. No side effects of Advantan were reported. In an infant with newly diagnosed eczema, Advantan was safe and effective in alleviating lesions and scratching severity and restoring sleep.
Department of Pediatric Dermatology, Hospital del Niño Jesús, Madrid, Spain. atorrelo@aedv.es
A
A
Torrelo
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004485:Eczema / Q000150:complications / Q000188:drug therapy*; D000091344:Filaggrin Proteins; D006801:Humans; D007223:Infant; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012893:Sleep Wake Disorders / Q000209:etiology*
D000893:Anti-Inflammatory Agents; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; C078007:methylprednisolone aceponate; D008775:Methylprednisolone